Should sponsors invest in upgrading health systems and/or buying existing vaccines rather than make an advance market commitment?
Sponsors should do both. Buying existing vaccines and increasing vaccine coverage would save millions of lives right away, as well as increasing private sector confidence that they can invest in new vaccines. Because there is no impact on the budget of making an advance market commitment, unless and until the vaccine is available, sponsors should in the meantime continue with other investments to save lives and increase market certainty.
Related Questions
- Can buying groups or health systems purchase multiple LatexDrugs accounts and are there any pricing discounts for these purchases?
- Should sponsors invest in upgrading health systems and/or buying existing vaccines rather than make an advance market commitment?
- What if I need help upgrading my existing data collection systems prior to implementing ERS?
